Newer methods using fluciclovine and PSMA-targeted radiotracers have preliminarily demonstrated great promise in primary and recurrent staging of prostate cancer.
However, their superior efficacy awaits confirmation in larger series. Newer prostata CT have increased detection accuracies for small, incipient metastatic foci. Efforts should be aimed at defining their natural history as well as responsiveness and impact of metastasis-directed therapy. Cancer statistics, CA Cancer J Clin.
Guideline for the management of clinically localized prostate cancer: update. J Urol. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. Eur Radiol. Magnetic resonance imaging-transectal ultrasound image-fusion biopsies accurately characterize the prostata CT tumor: correlation with step-sectioned radical prostatectomy specimens in patients. Detection of clinically significant prostate cancer using magnetic resonance imaging-ultrasound fusion targeted biopsy: a systematic prostata CT.
Performance of multiparametric magnetic resonance imaging in the evaluation and management prostata CT clinically low-risk prostate cancer. Urol Oncol. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol. MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study.
Lancet Prostata CT. Cook GJ, Fogelman I. The role of positron emission tomography in the management of bone metastases. Semin Nucl Med. Curr Radiopharm. Quantitative studies of bone using 18 F-fluoride and 99m Tc-methylene diphosphonate: evaluation of renal and whole-blood kinetics. Nucl Med Commun. J Nucl Med. J Bone Oncol. BJU Int. Clin Nucl Med. Prostata CT of acetate metabolism in tumor cells in relation to cell proliferation: prostata CT metabolism in tumor cells.
Nucl Med Biol. Value of [11C]choline-positron emission tomography for re-staging prostata CT cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography. Pharmacokinetics and radiation dosimetry of 18F-fluorocholine. Prostata CT Magn Reson Imaging.
Prostata CT of pelvic lymph node metastases in patients with clinically localized prostate cancer: comparison of [18F]fluorocholine positron prostata CT tomography-computerized tomography and laparoscopic radioisotope guided sentinel lymph node dissection. Scand Prostata CT Urol. Schiavina R, Martorana G. Jpn J Radiol.
Eur J Radiol. Mol Imaging Biol. Acta Oncol. Radiother Oncol. Radiat Oncol. Protocol-based image-guided salvage brachytherapy. Early results in patients with local failure of prostate cancer after radiation therapy. Strahlenther Onkol.
Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years. Adjuvant radiotherapy after salvage lymph node dissection because of nodal relapse of prostate cancer versus salvage lymph node dissection only.
Early salvage radiotherapy following radical prostatectomy. Journal of nuclear medicine: official publication. Soc Nucl Med. Bioorg Med Chem. Effect of prostata CT on the uptake of [methyl-3H]choline, [C] acetate and [18F]FDG in cultured prostate cancer cells.
Giovacchini G. Huang C, McConathy J. Radiolabeled prostata CT acids for oncologic imaging. Appl Radiat Isot. AntiaminoF-fluorocyclobutanecarboxylic acid: physiologic uptake patterns, incidental findings, and variants that may simulate disease. Characterization of primary prostate carcinoma by antiamino[ 18 Prostata CT -fluorocyclobutanecarboxylic acid anti[ 18 F] FACBC uptake.
Jpn J Clin Oncol. Anti[ 18 F]FACBC positron emission tomography-computerized tomography and In-capromab pendetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: results of a prospective clinical trial.
Acta Radiol. Nat Rev Urol. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. Prostate-specific membrane antigen expression as a predictor of prostata CT cancer progression. Hum Pathol. Bioorg Med Chem Lett.
Bioconjug Chem. Advancements in MR imaging of the prostate: from diagnosis to interventions. Abdom Imaging. Diagnostic efficacy of 68 Gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of consecutive patients with intermediate to high risk prostate cancer. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases.
Sensitivity, specificity, and predictors of positive 68Ga-prostate-specific prostata CT antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis.
Salvage radiotherapy for recurrent prostate prostata CT after radical prostatectomy. Adjuvant and salvage radiotherapy after prostatectomy: American society of clinical oncology clinical practice guideline endorsement. J Clin Oncol. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen.
Prostate-specific membrane antigen-radioguided surgery for metastatic lymph nodes in prostate prostata CT. PSMA-targeted imaging of prostate cancer: the best is yet to come. Clin Genitourin Cancer. Synthesis and biologic evaluation of novel 18F-labeled probes targeting prostate-specific membrane antigen for PET of prostate cancer.
In vivo imaging of prostate cancer using [68Ga]-labeled bombesin analog BAY Pokemet approach to metastatic prostate cancer. Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. Progression-free survival following stereotactic body radiotherapy for oligometastatic prostate cancer treatment-naive recurrence: a multi-institutional analysis.
Role of radical prostatectomy in metastatic prostate cancer: a review. Prostata CT Med Imaging Radiat Oncol. Download references. Correspondence to Roger Li. Reprints and Permissions. Li, R.